Abstract

BackgroundParkinson’s disease (PD) is a severe neurodegenerative disease associated with loss of dopaminergic neurons. Derivation of dopaminergic neurons from human embryonic stem cells (hESCs) could provide new therapeutic options for PD therapy. Dopaminergic neurons are derived from SOX− floor plate (FP) cells during embryonic development in many species and in human cell culture in vitro. Early treatment with sonic hedgehog (Shh) has been reported to efficiently convert hESCs into FP lineages.MethodsIn this study, we attempted to utilize a Shh-free approach in deriving SOX1− FP cells from hESCs in vitro. Neuroectoderm conversion from hESCs was achieved with dual inhibition of the BMP4 (LDN193189) and TGF-β signaling pathways (SB431542) for 24 h under defined culture conditions.ResultsFollowing a further 5 days of treatment with LDN193189 or LDN193189 + SB431542, SOX1− FP cells constituted 70–80 % of the entire cell population. Upon treatment with Shh and FGF8, the SOX1− FP cells were efficiently converted to functional Nurr1+ and TH+ dopaminergic cells (patterning), which constituted more than 98 % of the entire cell population. However, when the same growth factors were applied to SOX1+ cells, only less than 4 % of the cells became Nurr1+, indicating that patterning was effective only if SOX1 expression was down-regulated. After transplanting the Nurr1+ and TH+ cells into a hemiparkinsonian rat model, significant improvements were observed in amphetamine induced ipslateral rotations, apomorphine induced contra-lateral rotations and Rota rod motor tests over a duration of 8 weeks.ConclusionsOur findings thus provide a convenient approach to FP development and functional dopaminergic neuron derivation.Electronic supplementary materialThe online version of this article (doi:10.1186/s12929-016-0251-6) contains supplementary material, which is available to authorized users.

Highlights

  • Parkinson’s disease (PD) is a severe neurodegenerative disease associated with loss of dopaminergic neurons

  • We conducted a preliminary screening study whereby neural marker expression of human embryonic stem cells (hESCs) was analyzed after treatment with increasing dosages (1, 2 and 5nM) of LDN193189 for varying durations of 24 h, 48 h and 72 h

  • Neural plate (NP) markers: IRX3, SIX3, and OTX2; floor plate (FP) markers: FOXA2, and NTN1, and general neuroepithelial cell markers: SOX2 and PAX6 are all highly expressed after 5 days of culture (Fig. 1g)

Read more

Summary

Introduction

Parkinson’s disease (PD) is a severe neurodegenerative disease associated with loss of dopaminergic neurons. Derivation of dopaminergic neurons from human embryonic stem cells (hESCs) could provide new therapeutic options for PD therapy. Dopaminergic neurons are derived from SOX− floor plate (FP) cells during embryonic development in many species and in human cell culture in vitro. Methods: In this study, we attempted to utilize a Shh-free approach in deriving SOX1− FP cells from hESCs in vitro. Results: Following a further 5 days of treatment with LDN193189 or LDN193189 + SB431542, SOX1− FP cells constituted 70–80 % of the entire cell population. Upon treatment with Shh and FGF8, the SOX1− FP cells were efficiently converted to functional Nurr1+ and TH+ dopaminergic cells (patterning), which constituted more than 98 % of the entire cell population. PD is typically managed pharmacologically with dopaminergic agonist replacement or by increasing production of dopamine in surviving dopaminergic neurons through administration of the dopamine

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call